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S254 Poster Session IThe median days for pheresis was 1 day (range, 1-3). The median
SC dose collected was 4 x 106 CD34+ cells/ Kg (range, 2.5 – 14.3).
The median CD-34+ peripheral blood count on the 1st day collec-
tion with P was 22.4/uL. In contrast the median peripheral blood
CD-34+ cell count on the day of failed collection was 6.2 /uL. The
average increase using P was 14.9 CD-34+ cells/uL. We collected
$ 2.5 x 106 CD34+ cells/Kg on 4/5 pts with HD, 13/17 pts with
MM and 16/27 pts with NHL. 16 pts (33%) collected\ 2.5 x 106
CD34+ cells/Kg, with median cell dose of 1.4 x 106 CD34+ cells/
Kg (range, 0.4-2.2). The median number of days of pheresis was 2
days (range, 1-4). For these16 pts the median CD-34+ count on
the day of unsuccessful collection was11.2 /uL, compared to 8.3/
uL with use of P and GCSF. The common side effects attributed
to P were diarrhea, fatigue, thrombocytopenia and bone pain; ob-
served in 12%, 8%, 8% and 6% pts, respectively. 43/ 49 pts pro-
ceeded to an autologus SC transplant, 34 pts received $ 2.5 x 106
CD34+ cells/Kg. Thirty two of these pts used the P collection as
the only source of SC. Two pts had their P mobilized SC combined
with a previous suboptimal SC collection. Nine pts received\2.5 x
106 CD34 + cells/Kg; 4 pts received P mobilized SC alone, 5 pts re-
ceived P mobilized SC combined with their previously mobilized
SC. All pts received GCSF from day +6 till WBC engraftment.
The median days of WBC and platelet engraftment were day +11
(range, 9-13 days) and day +16 (range, 11-77 days), respectively.
With a median follow up of 13.7 months, long term engraftment
data is available on 27 pts. The median white cell count, hemoglobin
and platelet count 1 year after transplant was 4.7 x 109/L, 12.2 g/dL
and 109 x109/L, respectively. To date 15 pts have evidence of disease
progression. Two patients have developed MDS/AML post trans-
plant. Failure to increase peripheral CD34 count after P when com-
pared to previous attempts may predict unsuccessful mobilization.
P is well tolerated with minimal side effects, acceptable time to en-
graftment and acceptable peripheral blood counts at 1 yr after the
transplant.134
OUTCOMES FOLLOWING SALVAGE AUTOLOGOUS STEM CELL TRANS-
PLANT (SCT) FOR MULTIPLE MYELOMA
Silva Rondon, C., Hassoun, H., Chimento, D., Jia, X., Giralt, S.,
Landau, H.J. Memorial Sloan-Kettering Cancer Center, New York, NY
Background: High-dose therapy and SCT has improved the pro-
gression-free (PFS) and overall survival (OS) of patients with multi-
ple myeloma (MM). However all patients eventually develop disease
recurrence. In the era of effective novel agents (such as bortezomib,
lenalidomide and thalidomide), the optimal salvage strategy is unde-
fined.
Methods: We retrospectively analyzed the outcomes of patients
who underwent salvage melphalan-based SCT for relapsed MM at
Memorial Sloan-Kettering Cancer Center.
Results: Between 1995 and 2011, 60 patients with MM received an
initial SCT and then second autograft for relapsed disease at our cen-
ter. Conditioning regimen consisted of melphalan 100 (N 5 9), 140
(N5 20) or 200mg/m2 (N5 31). Themedian age at 2nd SCTwas 59
years (range 36-75) and 58% (N 5 35) were male. At the time of 1st
and 2nd transplant, 14% (5/36) and 36% (14/39) of patients whowere
assessed with either karyotype or FISH had high risk cytogenetics
(including t (4;14), +1q, p53 loss, or del 13q by karyotype), respec-
tively. Median interval between first and salvage SCT was 32 mos
(range 7.1-88.7). Of evaluable patients, 78% (46/59) had chemother-
apy sensitive disease prior to salvage SCT and 22% were chemore-
sistant. Twenty-eight patients received maintenance following
salvage SCT, most often IMID-based, while 11 went on to receive
an allogeneic SCT, 3/11 patients were received maintenance prior
to allogeneic SCT. Response was assessed at 2-3 mos post-SCT
and 77% of evaluable patients achieved . 5 partial response (PR),
16% had stable disease (SD), and 7% progressed despite salvage
SCT. Following salvage SCT, 23 patients received maintenance
therapy and 11 went on to allogeneic SCT. The median PFS follow-
ing second autograft was 11.2 mos (95% CI: 7.6-14.5); the median
OS was 24 mos (95% CI: 19-42). Although the numbers were small,
high-risk cytogenetics, the interval from first to second SCT, che-
mosensitivity, response and whether patients received maintenancetherapy or allogeneic SCT following salvage autologous SCT did
not significantly impact PFS or OS in this data set.
Conclusions: Salvage SCT is an effective strategy for relapsed MM
following initial autograft and results in responses in the majority of
patients. Although OS and PFS following salvage SCT is similar to
other salvage strategies, novel conditioning regimens and/or effec-
tive maintenance strategies may improve this approach.135
THE ROLE OF HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY
INDEX (HCT-CI) IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR
MULTIPLE MYELOMA
Lazaryan, A.1, Bolwell, B.1, Rybicki, L.2, Reu, F.1, Dean, R.1,
Duong, H.1, Sobecks, R.1, Tench, S.1, Copelan, E.1, Kalaycio, M.1
1Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 2Cleveland
Clinic, Cleveland, OH
Both autologous stem cell transplantation (ASCT) and novel
agents have improved outcomes for patients (pts) with multiple my-
eloma (MM). ASCT is often restricted to fitter pts due to concerns of
excessive treatment-related morbidity and mortality. Pre-transplant
risk-stratification based on comorbidity index (CI) has been recog-
nized as an important decision-making tool in pts with lymphoma
andMM. Although Charlson and hematopoietic cell transplantation
CI (HCT-CI) were previously correlated with post-ASCT toxicities
and length of hospital stay in pts with MM, the groups with higher
scores included fewer pts, limiting study interpretation. We evalu-
ated the prognostic significance of HCT-CI on treatment-related
morbidity (as determined by changes in pulmonary function, length
of hospital stay, and 100-day readmission rate), overall (OS), and
progression-free survival (PFS). Our analysis included 85 consecu-
tive pts (median age, 57 yrs; 68% males) with MM who underwent
ASCT at our institution from 01/2009 to 12/2010. 59% of pts
were in first complete or partial remission prior to ASCT. 65% of
pts had received.1 prior therapy. Median time from diagnosis to
ASCT was 13.4 months. Melphalan-based preparative regimen was
used in 61 pts, whereas others received Bu/Cy on a clinical trial.
24.7% had HCT-CI of 0; 37.6% pts had scores of 1-2; 37.6% pts
had scores$3. Incremental HCT-CI groups were associated with
worse performance status (p\0.001), lower absolute and%predicted
pre-transplant FEV1 (98% vs. 90% vs. 86%, p 5 0.01), lower abso-
lute and % predicted pre-transplant DLCO (91% vs. 78% vs. 66%,
p\0.001), lower % predicted post-transplant DLCO (82% vs. 60%
vs. 75%, p\0.001), longer hospital stay (15 vs. 16 vs. 18 days, p 5
0.03), and faster platelet recovery (17 vs. 12 vs. 12 days, p 5 0.007).
With median follow up of 12 months, 12 pts were readmitted within
100-days of discharge, 12 pts died (9 relapses, 1 heart failure, 1 sepsis,
1 subdural hematoma) with 2 deaths within 100-days from ASCT,
and 12 pts progressed. None of the 3 non-relapse deaths occurred
in the lowest HCT-CI group (two inHCT-CI$3). HCT-CI groups
did not differ by pt readmissions, OS, PFS, and% changes in Pulmo-
nary Function Tests pre- and post-ASCT (all p.0.3). With over
a third of our study pts having HCT-CI$3, we detected no associa-
tion between higher HCT-CI scores and major clinical outcomes.
Our data demonstrate the safety of ASCT in pts with MM who
have higher pre-transplant HCT-CI.136
VINORELBINE-CYCLOPHOSPHAMIDE COMPARED TO CYCLOPHOSPHA-
MIDE IN PERIPHERAL BLOOD STEM CELL MOBILIZATION
Soh, T.G.1, de Mel, S.P.2, Tan, L.K.1 1National University Health Sys-
tem, Singapore, Singapore; 2National University Health System, Singa-
pore, Singapore
Background: High dose therapy followed by autologous stem cell
rescue is the standard of care for transplant eligible patients with
plasma cell myeloma. High dose cyclophosphamide (Cy) at 4-
7mg/m2 with granulocyte colony stimulating factor (GCSF) has
been shown to be an effective regimen for stem cell mobilization de-
spite associated haematologic toxicity. Vinorelbine 25mg/m2 in
Poster Session I S255combination with Cy 1500mg/m2 (Vino-Cy) is also an effective mo-
bilization regimen which is postulated to be better tolerated.
There have been no studies to our knowledge comparing Vino –
Cy with Cy as a mobilization regimen. In our institution, Cy with
GCSF was the mobilization regimen of choice before 2007. Vinor-
elbine - Cy gained preference since late 2006.We performed a retro-
spective analysis of mobilisation outcomes using Vino- Cy at the
doses described above compared to Cy at our institution.
Methods: Patient data was extracted from our institutional database.
Eight patients underwent mobilization using the Cy-GCSF regimen
while 37 patients had Vino-Cymobilization using GCSF or Pegfilgras-
tim.
Results:The median age of the Vino-Cy patients at the time of har-
vest was 54 years, 12 patients were female and the median weight was
60.5 Kg. Themedian age of the Cy patients was 55 years and two pa-
tients were female, the median weight was 60 Kg. A greater median
CD34+ stem cell collection and a shorter median time to completion
of harvest was seen using Vino-Cy compared to Cy (Table 1). There
was also minimal variability in the timing of the harvest for the Vino-
Cy group as suggested by a standard deviation of 0.63.
Table. Mobilisation Outcomes with Vino-Cy and Cy
Day of Protocol No. of Days taken
Harvest Took Place to harvestCyCD34+/KgCyVino-Cy Vino-Cy Vino-CyMedian 9 2 3 12.8 5.5
Mean 8.5 1.8 2.4 13.2 7.8
Minimum 7 1 1 5.4 0.48
Maximum 9 3 0.94 32.5 6.39Discussion. Our data suggest that vinorelbine-Cy is superior to
Cy based on the higher CD34+ stem cell collection (more than ade-
quate for tandem transplant) and earlier completion of harvesting.
The timing of harvest is also highly predictable with Vino-Cy. Pro-
spective analyses are required to determine if Vinorelbine-Cy mobi-
lization confers a survival benefit over Cy.137
THROMBOTICMICROANGIOPATHY (TMA) RELATED TO CYTOMEGALOVI-
RUS (CMV) IS A RARE BUT SERIOUS CONDITION AFTER AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT)
Katragadda, L.1, Alejandro, R.1, Muzaffar, J.1, Kumar, N. Sanath1,
Barlogie, B.1, Cottler-Fox, M.2, Anaissie, E.J.1 1University of Arkansas
for Medical Sciences, Little Rock, AR; 2University of Arkansas for Medical
Sciences, Little Rock, AR
Introduction:TMA is a rare condition that has been associated with
CMV infection in solid organ and allogeneic stem cell transplant re-
cipients. Very little is known about TMA in ASCT recipients.
Methods: We retrospectively reviewed the medical records of all
ASCT recipients at our institution between April 2008 and June
2010 with a positive quantitative plasma polymerase chain reaction
test (qPCR) for CMV deoxyribonucleic acid (DNA). For a diagnosis
of CMV-related TMA we required the presence of schistocytes on
peripheral smear, laboratory evidence of hemolysis and ongoing
CMV infection. We excluded those with other known causes for
TMA (disseminated intravascular coagulation, drugs, malignant hy-
pertension and others).
Results: During the time period examined, 1254 patients with he-
matological cancer underwent melphalan-based ASCT. Reactiva-
tion of CMV was documented in 190 patients (131 within the first
6 months after ASCT, and 59 .6 months after ASCT while receiv-
ing non-myeloablative chemotherapy). Peripheral schistocytosis was
noted in 18 of the 190 patients (9.5%) of whom 13were excluded due
to the presence of other potential causes of TMA, leaving 5 patients
qualified as having CMV-related TMA. All 5 patients had multiple
myeloma, with a median age of 56 years (range 48-67 years), and
a male to female ratio of 2:3. CMV-related TMA developed at a me-
dian of 21 days after ASCT and presented with altered mental status
(3), acute renal failure requiring hemodialysis (3), hepatitis (2), myo-
cardial infarction, bilateral ischemic stroke (1). The clinical manifes-tations of CMV infection in these five patients included
thrombocytopenia (5), fever (4), diarrhea (4), pancytopenia (3) and
pneumonitis (1). The mean CMV qPCR at TMA diagnosis was
7250 DNA copies/ml (range 1250 to 11800 DNA copies/ml). Three
patients died at a mean of eight days after diagnosis (range 5-13 days)
with persistent CMV infection by CMV qPCR while receiving gan-
ciclovir and/or foscarnet. One of the two survivors responded to gan-
ciclovir alone while the other patient received ganciclovir and
rituximab and underwent plasmapheresis. Both survivors cleared
their CMV infection.
Conclusion:CMV-relatedTMA is a rare but serious and potentially
fatal complication in ASCT recipients. This condition should be
considered in the differential diagnosis of TMA because timely ini-
tiation of anti-viral therapy may improve outcome.138
INFECTIONS FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION
FOR HODGKIN’S LYMPHOMA
Seo, S.1, Kimball, L.E.1, Xie, H.2, Weiss, A.A.1, Dahlgren, C.1,
Davis, C.2, Boeckh, M.J.1,2,3, Pergam, S.A.1,2,3 1Fred Hutchinson Cancer
Research Center, Seattle, WA; 2Fred Hutchinson Cancer Research Center,
Seattle, WA; 3University of Washington, Seattle, WA
Background: Autologous stem cell transplantation (ASCT) is
a treatment option for refractory or relapsed Hodgkin lymphoma
(HL). The epidemiology of infectious complications following
ASCT in this population are unknown, thus we set out to identify
the incidence and prevalence of infections in patients with HL re-
ceiving an ASCT.
Patients and Methods: We retrospectively reviewed records from
patients who underwent ASCT for HL at our institution between 1/
1996 and 8/2009. Patients received acyclovir, neutropenic and PCP
prophylaxis and weremonitoredweekly for pp65 antigenemia early af-
ter ASCT.The probability of infections was assessed using cumulative
incidence estimates and incidence rates were calculated with 95% con-
fidence intervals (CI) estimated using a Poisson distribution.
Results: A total of 171 patients had a median of 673 days of follow-
up post-ASCT (range: 357-1592 days). There were a total of 622 in-
fections that occurred in 151 patients (89%), of which 323/622
(51.9%) were proven/probable cases. The cumulative incidence of
any infection was 58% at 90 days and 81% at 1 year after ASCT.
In the early period, bacteremia and CMV pp65 antigenemia were
most frequent, occurring in 29% and 31% (CMV seropositives) re-
spectively by day 90. Serious invasive infections occurred in 20/177
(11%) patients (24 total infections: GNR bacteremia 7; invasive fun-
gal disease 6; lower tract infection 5; typhlitis 2; CMV disease 2;
HHV-6 encephalitis 1; PCP 1). Sinopulmonary infections made up
more than 50% of all events, with cumulative incidence ranging
from 17% (sinusitis) to 15% (respiratory virus infections) at 1 year.
Conclusions: Infections are a frequent complication following
ASCT for HL with serious invasive disease occurring in 11% of pa-
tients. Bacterial infections and CMV antigenemia were the most
common infections in the early post-transplant period, while sino-
pulmonary infections were the most prevalent late infections.139
ORTHOTOPIC HEART TRANSPLANT FACILITATED AUTOLOGOUS HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION IN LIGHT-CHAIN AMYLOID-
OSIS
Kamble, R.T.1, Carrum, G.1, Rice, L.2, McCarthy, J.2, Baker, K.3,
Ramos, C.A.1, Adrogue, H.4, Estep, J.D.5 1Baylor College of Medicine, The
Methodist Hospital, Houston, TX; 2Weill Cornell Medical College, The
Methodist Hospital, Houston, TX; 3The Methodist Hospital, Houston, TX;
4JC Walter Jr Transplant Center, The Methodist Hospital, Houston, TX;
5JC Walter Jr Transplant Center, The Methodist Hospital, Houston, TX
Dominant cardiac involvement by primary systemic amyloidosis
(AL) precludes effective AL treatment and is associated with short
survival. Three patients who presented with severe cardiac dysfunc-
tion as their major AL manifestation underwent orthotopic heart
